These agents, including osimertinib, aumolertinib, furmonertinib, befotertinib, lazertinib, and rilertinib, have since become the new standard first‐line treatment for patients with advanced EGFR‐mutated NSCLC [9, 10, 11, 12, 13, 14, 15, 16, 17]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.